Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
51 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Binge Eating Disorder - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Binge Eating Disorder - Pipeline Review, H2 2014', provides an overview of the Binge Eating Disorder's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Binge Eating Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Binge Eating Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Binge Eating Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Binge Eating Disorder Overview 6 Therapeutics Development 7 Pipeline Products for Binge Eating Disorder - Overview 7 Pipeline Products for Binge Eating Disorder - Comparative Analysis 8 Binge Eating Disorder - Therapeutics under Development by Companies 9 Binge Eating Disorder - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Binge Eating Disorder - Products under Development by Companies 13 Binge Eating Disorder - Companies Involved in Therapeutics Development 14 Teva Pharmaceutical Industries Limited 14 Shire Plc 15 Omeros Corporation 16 Heptares Therapeutics Ltd. 17 Lightlake Therapeutics Inc. 18 Binge Eating Disorder - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 27 armodafinil - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 lisdexamfetamine dimesylate - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 LT-12 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 OMS-527 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule Targeting Orexin 1 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Binge Eating Disorder - Recent Pipeline Updates 37 Binge Eating Disorder - Dormant Projects 43 Binge Eating Disorder - Discontinued Products 44 Binge Eating Disorder - Product Development Milestones 45 Featured News & Press Releases 45 Nov 05, 2013: Positive Top-line Results Shown for Vyvanse Capsules in Adults with Binge Eating Disorder 45 May 23, 2013: Lightlake Therapeutics Announces Presentation Of Binge Eating Disorder Treatment Phase II Trial Results At APA 2013 Annual Meeting 47 May 17, 2013: Shire To Present Scientific Data On Vyvanse At 166th APA Annual Meeting 2013 47 Mar 27, 2013: Lightlake Therapeutics Announces Phase II Clinical Trial Results Of Treatment For Binge Eating Disorder Accepted At American Psychiatric Association Annual Meeting 48 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 51 Disclaimer 51
List of Tables Number of Products under Development for Binge Eating Disorder, H2 2014 7 Number of Products under Development for Binge Eating Disorder - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Binge Eating Disorder - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 14 Binge Eating Disorder - Pipeline by Shire Plc, H2 2014 15 Binge Eating Disorder - Pipeline by Omeros Corporation, H2 2014 16 Binge Eating Disorder - Pipeline by Heptares Therapeutics Ltd., H2 2014 17 Binge Eating Disorder - Pipeline by Lightlake Therapeutics Inc., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 26 Binge Eating Disorder Therapeutics - Recent Pipeline Updates, H2 2014 37 Binge Eating Disorder - Dormant Projects, H2 2014 43 Binge Eating Disorder - Discontinued Products, H2 2014 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
